[{"id":"4f75b0a7-7178-47a9-b387-b0e643dacaa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02280811","created_at":"2021-01-18T10:44:29.678Z","updated_at":"2024-07-02T16:37:18.118Z","phase":"Phase 1/2","brief_title":"T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers","source_id_and_acronym":"NCT02280811","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E6 TCR • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2014","start_date":" 10/14/2014","primary_txt":" Primary completion: 06/28/2016","primary_completion_date":" 06/28/2016","study_txt":" Completion: 06/28/2016","study_completion_date":" 06/28/2016","last_update_posted":"2017-09-06"}]